### Hydrazone Derivatives of Benzofuran: Synthesis and Their Antimicrobial Activities

2

# 3 Abstract

A series of (*Z*)-1-benzo[*b*]furan-2-yl-3-(substituted phenyl)prop-2-en-1-one 1-phenylhydrazone derivatives ( $C_1$ - $C_{12}$ ) of benzofuran were synthesized in satisfactory yield and pharmacologically evaluated for their *in vitro* antimicrobial activity. All the synthesized compounds were in good agreement with elemental and spectral data. A majority of the tested compounds showed good to moderate antimicrobial activity against all tested pathogenic bacterial and fungal strains.

9

10 Keywords: Benzofuran, Phenylhydrazone, Antimicrobial activity

11

### 12

13

# 14 Introduction

Antimicrobials reduce or completely block the growth and multiplication of bacteria. This has
made them unique for the control of deadly infectious diseases caused by a variety of pathogens.

17 They have transformed our ability to treat infectious diseases such as pneumonia, meningitis, tuberculosis, malaria and AIDS [1]. These agents are those inhibitory chemicals which are 18 19 employed to kill microorganisms or prevent their growth. Infectious diseases account for 20 approximately one-half of all deaths in tropical countries. Although deaths from bacterial and 21 fungal infections have dropped in the developed world, these are still major causes of death in the developing world [2]. In addition, primary and opportunistic fungal infections continue to 22 23 increase rapidly because of the increased number of immune compromised patients (AIDS, 24 cancer and transplants) [3]. According to WHO, each year 1.4 million children died of gut 25 infections and diarrhoea caused by gram-negative bacteria like Pseudomonas, Salmonella, Shigellae and gram positive rods like Corynebacterium diptheriae [4]. Decades of antibiotic use 26 27 have resulted in the development of widespread resistance to commonly prescribed antibacterial 28 agents[5]. Therefore, there is a need to develop new, potent, fast-acting antimicrobial drugs with 29 low toxicity. In the design of new compounds, development of hybrid molecules through the 30 combination of different pharmacophores in one structure may lead to compounds with increased antimicrobial activity [6]. 31

Despite numerous attempts to develop new structural prototype in the search for more effective antimicrobials, benzofuran still remain as one of the most versatile class of compounds

against microbes and therefore, are useful substructures for further molecular exploration. 34 Benzofuran's literature is enriched with progressive findings of the moiety in respect of 35 antimicrobial activity [7]. Benzofuran and its derivatives constitute the most versatile and 36 valuable source of antimicrobial compounds. They appear to transcend the chemotherapeutic 37 boundaries of other antiparasitic drugs with a spectrum of activity that includes the majority of 38 fungi, bacteria, protozoa and helminthic species. The prime objective for the current study is to 39 developmovel derivatives of benzofuran moiety and finally screen them against different 40 microbial strains (bacteriaand fungi) at variable concentrations. The rationale for the study 41 includes the designing of the derivatives having some common structural features that are 42 important for the compound to exhibit an antimicrobial activity that includes the following:[8– 43 10] 44

45 1. A lipohilic bicyclic aromatic ring system.

46 2. Another bulky lipophilic group (e.g. phenyl, *tert*butyl)as a side chain.

3. Two lipophilic domain linked by a spacer of appropriatelength with polar centre at defined
position,for example, Naftifine, Butenafine, Terbinafine, Debacarb, Penicillins and
Cephalosporins.

In view of the above mentioned facts and in continuation of our interest in the synthesis 50 51 of heterocycles containing benzofuran moiety, to identify new candidates that may be of value in designing new, potent, selective and less toxic antimicrobial agents, we report herein the 52 53 synthesis and antimicrobial evaluation of some novel structure hybrids incorporating the benzofuran moiety with phenylhydrazone through different linkages. This combination was 54 55 suggested in an attempt to investigate the influence of such hybridization and structure variation on the anticipated biological activities, hoping to add some synergistic biological significance to 56 57 the target molecules. The substitution pattern of benzofuran ring was carefully selected so as to confer different electronic environment to themolecules. 58

59

### 60 **Experimental**

All the solvents were of AR grade and were obtained from SDFCL Ltd., Himedia, Central drug
House (p) Ltd and Loba-chemicals. All the microorganisms used in the present screening were
procured from the Department of Microbiology, Gulbarga University, Gulbarga. Melting points
were determined inopen capillary tubes and are uncorrected. All the compounds were subjected

to elemental analysis (CHN) and the measured values agreed within  $\pm 0.4\%$  with the calculated 65 ones. Thin layer chromatography was performed on silica gel G (Merck). The spots were 66 developedin an iodine chamber and visualized with an ultraviolet lamp. The solvent systems 67 used were benzene: acetone (8:2, v/v) and toluene: ethylacetate: formic acid (5:4:1, v/v). Ashless 68 Whatman No. 1 filter paper was used for vacuum filtration. The IR spectra were recorded in KBr 69 pelletson a (BIO-RAD FTS 135) WIN-IR spectrophotometer. The FAB mass spectra of all the 70 71 compounds were recorded on a JEOL SX102/DA-600mass spectrometer using argon/xenon (6 kV, 10 mA) as the FAB gas. The 1H-NMR spectra were recorded on a Bruker model DPX 300 72 FT-NMR spectrometer in CDCl<sub>3</sub> using tetramethylsilane (Me<sub>4</sub>Si, TMS) asan internal standard. 73 74 The chemical shifts are reported in the  $\delta$  ppmscale [18]. The physicochemical & spectral data of the synthesized title compounds were listed in Table 1 & 2. 75

### 76 General procedure for the synthesis of 1-(1-benzofuran-2-yl) ethanone (B) [7]

The mixture of salicylaldehyde (0.1 mole) (**A**), chloroacetone (0.1 mole) and anhydrous potassium carbonate (30 g) were gently refluxed in dry acetone (150 ml) for 13 hr. The reaction product after cooling was filtered and the filtrate on the removal of the solvent under reduced pressure furnished 2-acetyl benzofuran as dark yellow colored solid. The product obtained was recrystallized from petroleum ether.

# General procedure for the synthesis of (Z)-1-benzo[b]furan-2-yl-3-(Substituted phenyl) prop-2-en-1-one (B<sub>1</sub>-B<sub>12</sub>)

A solution of 2-acetyl benzofuran (1.6 ml, 0.01 mole) and various aromatic aldehyde (0.01 mole) in ethanol (4.6 ml) was cooled to 5 to  $10^{0}$ C in an ice bath. The cooled solution was treated with drop wise addition of aqueous sodium hydroxide (4 ml, 50%). The resulting dark solution was diluted with ice water and carefully acidified using diluted hydrochloric acid. The benzofuran analogues of chalcone which were crystallized were collected by filtration after washing with sodium bicarbonate and water. It was further purified by re-crystallization from ethanol.

90 General procedure for the synthesis of (Z)-1-benzo[*b*]furan-2-yl-3-(Substituted 91 phenyl)prop-2-en-1-one-1-Phenylhydrzone (C<sub>1</sub>-C<sub>12</sub>)

A mixture of phenylhydrazine hydrochloride (1.44 g, 0.01 mole), sodium acetate (0.82 g, 0.01
mole) in ethanol (10 ml) was stirred at RT for 10 min. To this ethanolic solution, (Z)-1-

- benzo[b]furan-2-yl-3-(Substituted phenyl)prop-2-en-1-one  $(\mathbf{B_1}-\mathbf{B_{12}})$  (0.01 mole) was added
- slowly. The resulting reaction- mixture was allowed to stir for about 2 hr and completion of the

96 reaction was monitored by TLC. The reaction-mixture was then poured into ice water (50 ml) 97 where upon the crude compound was precipitated as yellow solid. The residue obtained after 98 filtration was washed with water and dried. The crude product was purified by recrystallization 99 from absolute alcohol.

# 100 Biological Activity

101 All the synthesized compounds were tested for their *in vitro* antimicrobial activity against the 102 bacteria Enterococcus fecalis ATCC-29212, Bacillus subtilus, Escherichia coli ATCC-25923, and Pseudomonas aurigenosa ATCC-27853 in the nutrient agar media, and fungi Candida 103 albicans NLTM-3431, Aspergillus niger MTCC 281in Sabouraud dextrose medium at 100 and 104  $50 \mu g/mL$  concentrations by using serial plate dilution method (11, 12). The minimum inhibitory 105 concentrations (MIC's) values were determined by comparison to Amoxycillin and Gresiofulvin 106 107 as reference drugs for bacterial and fungal activity, respectively, as shown in Tables 3. Standard antibiotic Amoxycillin and Gresiofulvinwere used as reference drug at 50 and 25 µg/mL 108 concentrations. The minimum inhibitory concentration (MIC) was defined as the lowest 109 concentration of the compounds that inhibited visible growth of microorganisms on the plate. 110

111

## 112 **RESULTS AND DISCUSSION**

### 113 Chemistry

(Z)-1-benzo[*b*]furan-2-yl-3-(Substituted phenyl) prop-2-en-1-one-1-Phenylhydrzone were prepa-114 115 red according to the procedure outlined in Scheme 1. The required 1-(1-benzofuran-2-yl) ethanone (B) was synthesized by reacting salicylaldehyde (A) and dry chloroacetone in the 116 117 presence of anhydrous potassium carbonate. To a cooled solution of 1-(1-benzofuran-2-yl) ethanone (B) and aromatic aldehydes in ethanol, sodium hydroxide(50%) was added drop wise to 118 119 yield the chalcones of benzofuran  $(B_1-B_{12})$ . These chalcones were stirred at room temperature with phenylhydrazine hydrochloride and sodium acetate in ethanol for 2 hours to precipitate the 120 121 title compounds  $(C_1-C_{12})$ . The product was then recrystallized from absolute ethanol. The structure of synthesized compounds was confirmed by elemental analysis and spectral data (IR, 122 123 <sup>1</sup>H NMR, MS).

### 124 Antimicrobial activity

125 The investigation of antibacterial and antifungal screening data revealed that all the tested 126 compounds ( $C_1$ - $C_{12}$ ) showed good to moderate inhibition at 50-100 µg/mL in DMSO. The 127 compoundsC<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>10</sub>, C<sub>11</sub>& C<sub>12</sub>showed comparatively moderate to good activity against all the bacterial and fungal strains. The good activity is attributed to the presence 128 129 of pharmacologically active 4-nitro ( $C_1$ ), 2-chloro ( $C_2$ ), 4-chloro ( $C_3$ ), 4-methoxy ( $C_5$ ), 4-Bromo  $(C_7)$ , 4-methyl  $(C_8)$ , 4-hydroxy  $(C_{10})$ , 2-hydroxy  $(C_{11})$ , 2-methyl  $(C_{12})$  groups attached to phenyl 130 group at position 3 of the benzofuran ring. When these groups were replaced by 3-chlorophenyl 131 (C4), phenyl (C6) and 3-nitropheny (C9), a sharp decrease in activity against all of the microbial 132 133 strains were observed. **CONCLUSION** 134 Thus, various derivatives of phenylhydrazone ( $C_1$ - $C_{12}$ ) were prepared with the objective of 135 developing better antimicrobial agents. All the derivatives were found to have a promising class 136 137 of compounds with an interesting pharmacological profile. Among these the compounds,  $C_8$  and  $C_{11}$  showed maximum antibacterial and antifungal activity, respectively. Hence, it is clear from 138 structure activity relationship (SAR), that the compounds synthesized showed significant 139

- antimicrobial activity stating the importance of electron withdrawing substituent's on the phenyl 140 group. In conclusion, the benzofuran incorporated hydrazone derivatives can be regarded as a 141 newer class of antimicrobial agents. They were also found to be less toxic which indicates better 142 tolerability of the compounds having strong future prospects. 143
- 144

#### References 145

- 146
- 1. S. J. Gilani, S. A. Khan, S. P. Verma, P. Mullick, O. Alam, N. Siddiqui, Synthesis and in 147 vitro antimicrobial activity of novel N-(6- chlorobenzo [d] thia zol-2-yl) hydrazine 148 carboxamide derivatives of benzothiazole class, Journal of Enzyme Inhibiton and Medicinal 149 *Chemistry*, 26(3), pp. 332-340, 2011. 150
- 2. S. J. Gilani, S. A. Khan, N. Siddiqui, Synthesis and in vitro antimicrobial evaluation of 151 condensed heterocyclic 6-substituted 1,2,4-triazolo-[3,4-b]-1,3,4- thiadiazole and 1,3,4-152 oxadiazole derivatives of isoniazid, *Acta Poloniae Pharmaceutica*, 68(2), pp. 205-211, 2011. 153
- 154 3. S. J. Gilani, D. P. Maurya, D. Katiyar, R. Goel, K. Nagarajan, S. A. Khan, Synthesis, Antifungal and Toxicity Screening of Newer Isoniazid Derivatives, *Medicinal chemistry*, 155 4(4), pp.428-434, 2014. 156

- T. Nogrady , F.D.Weaver, Medicinal Chemistry: A Molecular & Biochemical Approach.
   Oxford University Press, pp. 559–582, 2005.
- L.S.Thomasco, C.R.Gadwood, E.A.Weaver, J.M. Ochoada, C.W. Ford, G.E. Zurenko,
   J.C.Hamel, D. Stapert, J.K.Moerman, R.D. Schaadt, B.H. Yagi BH, The synthesis and
- 161 antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues, *Bioorganic and*
- 162 *Medicinal Chemistry Letters*, *13*, pp.4193–4196, 2003
- 163 6. T. Onkol, D.S. Dogruer, L. Uzun, S. Adak, S. Ozkan, M.F. Sahin, Synthesis and
   164 antimicrobial activity of new 1,2,4-triazole and 1,3,4-thiadiazole derivatives, *Journal of* 165 *Enzyme Inhibiton and Medicinal Chemistry*, 23, pp.277–284, 2008.
- 7. R. Basawaraj, S.N. Goled, G. Parmeshwarappa, S.S.Sangapure, Synthesis and biological
  activity of some pyridyl substituted benzofurans, *Indian Journal of Heterocyclic Chemistry*, *18*, pp.325-328,2009
- 8. P. Nussbaumer, I. Leitner, A. Stütz, Synthesis and structure-activity relationships of the
  novel homopropargylamine antimycotics, *Journal of Medicinal Chemistry*, *37*, pp.610–
  615,1994.
- P. Nussbaumer, I. Leitner, K. Mraz, A. Stütz, Synthesis and structureactivity relationships of
   side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central
   amino function, *Journal of Medicinal Chemistry*, *38*, pp.1831–1836, 1995.
- 175 10. Y.U. Chongxi, Transdermal Delivery Systems of Beta-Lactam Antibiotics. International,
  176 Application No.: PCT.IB2006/054724 [Online] WO/2008/072032. Available at: http://
  177 www.wipo. int/pctdb/en/wo.jsp. Accessed on 27 July 2010.
- 178 11. A.L.Barry, Procedure for testing antimicrobial agents in agar media. in Antibiotics in
  179 Laboratory Medicine, Corian V.L. Ed., p. 1, Williams and Wilkins, Baltimore 1991.
- 180 12. S.R. Verma, K.Z. Khan, A.P. Singh, Antifungal Agents: Past, Present and Future Prospects,
- 181 National Academy of Chemistry and Biology, Lucknow, India, pp. 55, 1998.

Compounds	mpounds Substitution (R)		Mol.	MP	R <sub>f</sub>	% Yield	
•			Wt.	(°C)	-		
<b>B</b> <sub>1</sub>	p-Nitrobenzaldehyde	C <sub>17</sub> H <sub>11</sub> NO <sub>4</sub>	293	80	0.55	25.8	
<b>B</b> <sub>2</sub>	o-Chlorobenzaldehyde	$C_{17}H_{11}ClO_2$	283	73	0.67	29.4	
<b>B</b> <sub>3</sub>	p-Chlorobenzaldehyde	$C_{17}H_{11}ClO_2$	283	140	0.34	39.6	
$B_4$	<i>m</i> -Chlorobenzaldehyde	$C_{17}H_{11}ClO_2$	283	130	0.54	19.8	
B <sub>5</sub>	p-Anisaldehyde	$C_{18}H_{14}O_3$	278	172	0.78	33	
<b>B</b> <sub>6</sub>	Benzaldehyde	$C_{17}H_{12}O_2$	248	68	0.87	57.78	
<b>B</b> <sub>7</sub>	<i>p</i> -Bromobenzaldehyde	$C_{17}H_{11}BrO_2$	327	120	0.35	48.95	
<b>B</b> <sub>8</sub>	p-Tolualdehyde	$C_{18}H_{14}O_2$	262	85	0.66	39.84	
<b>B</b> 9	<i>m</i> -Nitrobenzaldehyde	$C_{17}H_{11}NO_4$	293	120	0.73	38.25	
B <sub>10</sub>	p-Salicyaldehyde	$C_{17}H_{12}O_3$	264	145	0.22	39.69	
B <sub>11</sub>	o-Salicyaldehyde	$C_{17}H_{12}O_3$	264	140	0.46	42.12	
B <sub>12</sub>	o-Tolualdehyde	$C_{18}H_{14}O_2$	262	60	0.37	18.32	
C <sub>1</sub>	p-Nitrobenzaldehyde	C <sub>23</sub> H <sub>17</sub> N <sub>3</sub> O <sub>3</sub>	382	95	0.66	94.77	
C <sub>2</sub>	o-Chlorobenzaldehyde	C <sub>23</sub> H17ClN <sub>2</sub> O	372	55	0.70	54.02	
C <sub>3</sub>	<i>p</i> -Chlorobenzaldehyde	$C_{23}H_{17}CIN_2O$	372	190	0.72	21.50	
C <sub>4</sub>	<i>m</i> -Chlorobenzaldehyde	C <sub>23</sub> H17ClN <sub>2</sub> O	372	135	0.65	47.84	
C <sub>5</sub>	p-Anisaldehyde	$C_{24}H_{20} N_2O_2$	368	145	0.55	37.77	
C <sub>6</sub>	Benzaldehyde	$C_{23}H_{18} N_2O$	338	100	0.47	38.46	
C <sub>7</sub>	<i>p</i> -Bromobenzaldehyde	C <sub>23</sub> H <sub>17</sub> Br N <sub>2</sub> O	417	140	0.43	50.83	
C <sub>8</sub>	p-Tolualdehyde	$C_{24}H_{20}N_2O$	352	125	0.69	76.98	
C <sub>9</sub>	<i>m</i> -Nitrobenzaldehyde	$C_{23}H_{17}N_3O_3$	383	190	0.73	41.25	
C <sub>10</sub>	p-Salicyaldehyde	$C_{23}H_{18}N_2O_2$	354	120	0.40	64.12	
C <sub>11</sub>	o-Salicyaldehyde	$C_{23}H_{18}N_2O_2$	354	125	0.45	28.00	
C <sub>12</sub>	o-Tolualdehyde	$C_{24}H_{20}N_2O$	352	85	0.45	71.30	

Elemental analysis were found to be within  $\pm 0.4\%$  of theoretical values.

Compounds	Substitution (R)	Spectral Data
C <sub>1</sub>	<i>p</i> -Nitrobenzaldehyde	IR (KBr, cm <sup>-1</sup> ):1535 & 1350 (-NO2), 2849 &
		2732 (Ar-CH), 1104 (C-O-C), 3310 (N-H); <sup>1</sup> H
		NMR (DMSO-d <sub>6</sub> , $\delta$ ppm): 7.36- 8.51 (m, 5H,
		Benzofuran), 7.21-7.32 (m, 5H, Ar-H).8.11
		(1H, s, NH); MS (m/z): 382(M <sup>+</sup> )
$C_2$	o-Chlorobenzaldehyde	IR (KBr, cm <sup>-1</sup> ):747 (-Cl), 2920 (Ar-CH), 1129
		(C-O-C), 3316 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm):7.32- 8.56 (m, 5H, Benzofuran), 7.20-
		7.28 (m, 5H, Ar-H).8.14 (1H, s, NH); MS
		$(m/z): 372 (M^+)$
$C_3$	p-Chlorobenzaldehyde	IR (KBr, cm <sup>-1</sup> ):757(-Cl), 2845 (Ar-CH),1088
		$(C-O-C)$ , 3314 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		npm):7 34- 8 56 (m 5H Benzofuran) 7 18-

194	Table 2	Spectral data of the title compounds $(C_1-C_{12})$

$C_2$	o-Chlorobenzaldehyde	IR (KBr, cm <sup>-1</sup> ):747 (-Cl), 2920 (Ar-CH), 1129
		(C-O-C), 3316 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm):7.32- 8.56 (m, 5H, Benzofuran), 7.20-
		7.28 (m, 5H, Ar-H).8.14 (1H, s, NH); MS
		(m/z): 372 (M <sup>+</sup> )
C <sub>3</sub>	<i>p</i> -Chlorobenzaldehyde	IR (KBr, cm <sup>-1</sup> ):757(-Cl), 2845 (Ar-CH),1088
		(C-O-C), 3314 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm):7.34- 8.56 (m, 5H, Benzofuran), 7.18-
		7.22 (m, 5H, Ar-H).8.15 (1H, s, NH); MS
		$(m/z): 372 (M^+)$
$C_4$	<i>m</i> -Chlorobenzaldehyde	IR (KBr, cm <sup>-1</sup> ):749 (-Cl), 2883 (Ar-CH), 1139
		(C-O-C), 3305 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm): 7.35- 8.58 (m, 5H, Benzofuran), 7.19-
		7.24 (m, 5H, Ar-H).8.13 (1H, s, NH); MS
		(m/z): 372 (M <sup>+</sup> )
$C_5$	p-Anisaldehyde	IR (KBr, cm <sup>-1</sup> ):2841 (OCH3-CH), 1109 (C-O-
		C), 3319 (N-H) ; <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm):7.36- 8.57 (m, 5H, Benzofuran), 7.13-
		7.18 (m, 5H, Ar-H).8.12 (1H, s, NH); MS
		(m/z): 368 (M <sup>+</sup> )
$C_6$	Benzaldehyde	IR (KBr, cm <sup>-1</sup> ):3066 & 3025 (Ar-CH), 1131
		(C-O-C), 3317 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm):7.33- 8.51 (m, 5H, Benzofuran), 7.16-
		7.26 (m, 5H, Ar-H).8.15 (1H, s, NH); MS
		(m/z): 338 (M <sup>+</sup> )
$C_7$	<i>p</i> -Bromobenzaldehyde	IR (KBr, cm <sup>-1</sup> ):546-503 (-Br), 2851 (CH-Ar),
		1067 (C-O-C), 3308 (N-H); <sup>1</sup> H NMR (DMSO-
		$d_6$ , $\delta$ ppm):7.36-8.52 (m, 5H, Benzofuran),
		7.23-7.27 (m, 5H, Ar-H).8.17 (1H, s, NH); MS
		(m/z): 417 (M <sup>+</sup> )
$C_8$	<i>p</i> -Tolualdehyde	IR (KBr, cm <sup>-1</sup> ):2922 (CH3-CH), 2865 (Ar-
		CH), 3316 (N-H) , 1118 (C-O-C) ; <sup>1</sup> H NMR
		(DMSO-d <sub>6</sub> , $\delta$ ppm):7.37-8.54 (m, 5H,
		Benzofuran), 7.17-7.25 (m, 5H, Ar-H).8.17
		(1H, s, NH); MS (m/z): 352(M <sup>+</sup> ).
C9	<i>m</i> -Nitrobenzaldehyde	$IR (KBr, cm^{-1}):1350 (-NO2), 1150 (C-O-C),$
		3304 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm):7.36- 8.57 (m, 5H, Benzofuran), 7.21-

		7.27 (m, 5H, Ar-H).8.13 (1H, s, NH); MS
		$(m/z): 383 (M^+)$
C <sub>10</sub>	<i>p</i> -Salicyaldehyde	IR (KBr, cm <sup>-1</sup> ):3576 &3494 (-OH), 3021 (Ar-
		CH),1107 (C-O-C), 3309 (N-H); <sup>1</sup> H NMR
		(DMSO-d <sub>6</sub> , $\delta$ ppm): 7.33- 8.51 (m, 5H,
		Benzofuran), 7.21-7.25 (m, 5H, Ar-H).8.16
		(1H, s, NH); MS (m/z): 354(M <sup>+</sup> )
C <sub>11</sub>	o-Salicyaldehyde	IR (KBr, cm <sup>-1</sup> ):3468 & 3421 (-OH), 3069 (Ar-
		CH),1139 (C-O-C), 3319 (N-H) ; <sup>1</sup> H NMR
		(DMSO-d <sub>6</sub> , $\delta$ ppm):7.32-8.56 (m, 5H,
		Benzofuran), 7.14-7.19 (m, 5H, Ar-H).8.14
		(1H, s, NH); MS (m/z): 354 (M <sup>+</sup> )
C <sub>12</sub>	o-Tolualdehyde	IR (KBr, cm <sup>-1</sup> ):2926 (CH3-CH), 1087 (C-O-
		C), 3313 (N-H); <sup>1</sup> H NMR (DMSO-d <sub>6</sub> , $\delta$
		ppm):7.36- 8.54 (m, 5H, Benzofuran), 7.23-
		7.29 (m, 5H, Ar-H).8.18 (1H, s, NH); MS
		$(m/z)$ : 352 $(M^+)$ .

Compounds	zone of inhibition in mm and MIC in $\mu$ g/mL				zone of inhibition in	
	(Antibacterial)				mmand MIC in µg/mL	
					(Antifungal)	
	Enterococcus	Bacillus	Escherichia	Pseudomonas	Candida	Aspergillus
	fecalis	subtilus	coli	aurigenosa	albicans	niger
C <sub>1</sub>	16(50)	18(50)	14(50)	17(50)	19(50)	17(50)
C <sub>2</sub>	14(50)	17(50)	13(50)	18(50)	15(50)	19(50)
C <sub>3</sub>	18(50)	16(50)	19(50)	17(50)	18(50)	20(50)
C <sub>4</sub>	5(100)	3(100)	8(100)	7(100)	2(100)	6(100)
C <sub>5</sub>	17(50)	13(50)	15(50)	18(50)	16(50)	12(50)
C <sub>6</sub>	3(100)	7(100)	4(100)	6(100)	4(100)	9(100)
C <sub>7</sub>	18(50)	15(50)	14(50)	16(50)	13(50)	17(50)
C <sub>8</sub>	19(50)	20(50)	14(50)	17(50)	18(50)	15(50)
C9	9(100)	6(100)	4(100)	7(100)	6(100)	8(100)
C <sub>10</sub>	14(50)	12(50)	14(50)	19(50)	15(50)	19(50)
C <sub>11</sub>	13(50)	16(50)	18(50)	16(50)	20(50)	20(50)
C <sub>12</sub>	17(50)	18(50)	17(50)	15(50)	19(50)	16(50)
Amoxycillin	28(25)	24(25)	26(25)	27(25)	30(25)	29(25)
Griseofulvin	26(25)	27(25)	29(25)	26(25)	27(25)	26(25)

**Table 3** Antimicrobial activity of the synthesized title compounds  $(C_1-C_{12})$ 



